Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
Panagiota Economopoulou(National and Kapodistrian University of Athens), Paolo Bossi(Humanitas University), Anastasios Pantazopoulos(University General Hospital Attikon), Carlo Resteghini(Humanitas University), Cristiana Bergamini(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Cossu Rocca(European Institute of Oncology), Elena Colombo(Fondazione IRCCS Istituto Nazionale dei Tumori), Stefania Vecchio(Ospedale Policlinico San Martino), Μaria Anastasiou(National and Kapodistrian University of Athens), Aris Spathis(National and Kapodistrian University of Athens), Anastasios Kyriazoglou(Alexandra Hospital), Lisa Licitra(University of Milan), George Kavourakis(National and Kapodistrian University of Athens), F Caspani(Fondazione IRCCS Istituto Nazionale dei Tumori), Amanda Psyrri(National and Kapodistrian University of Athens), Pierluigi Bonomo(Azienda Ospedaliero-Universitaria Careggi), Ioannis Chatzidakis(University General Hospital Attikon), Federica Bertolini, Ioannis Kotsantis(National and Kapodistrian University of Athens), Daris Ferrari, Maria Prevezanou(University General Hospital Attikon), Roubini Zakopoulou(National and Kapodistrian University of Athens), Nerina Denaro(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 11
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
|Cancer|2020|1.3k